Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information from Novartis Ireland Ltd regarding Crizanlizumab, ADAKVEO, Phase III STUDY (CSEG101A2301) shows no superiority of crizanlizumab over placebo
Important Safety Information – ADAKVEO (Crizanlizumab)